Skip to main content
Selvita S.A. logo

Selvita S.A. — Investor Relations & Filings

Ticker · SLV ISIN · PLSLVCR00029 LEI · 25940057WQ9YP5MOQF28 WAR Professional, scientific and technical activities
Open in API
Filings indexed 1,179 across all filing types
Latest filing 2017-11-15 Interim / Quarterly Rep…
Country PL Poland
Listing WAR SLV

About Selvita S.A.

https://selvita.com/

Selvita S.A. is a preclinical contract research organization (CRO) providing integrated services for the pharmaceutical and biotechnology sectors. The company offers comprehensive solutions across the drug discovery and development continuum, from target validation to preclinical candidate nomination. Core drug discovery capabilities include medicinal chemistry, pharmacology, DMPK, and protein sciences, supporting a wide range of modalities such as small molecules, antibodies, and protein degraders. For drug development, Selvita provides analytical support for small and large molecules, formulation, microbiology services, and manufacturing for clinical trials. The company operates under GMP and GLP quality standards, offering flexible engagement models that range from standalone studies to fully integrated programs.

Recent filings

Filing Released Lang Actions
Raport skonsolidowany Grupy Selvita S.A. Q3 2017
Interim / Quarterly Report Classification · 100% confidence The document is a 'Skonsolidowane sprawozdanie finansowe' (Consolidated Financial Report) for the Q3 2017 period. It contains a detailed table of contents covering the balance sheet, income statement, cash flow, and management commentary (MDA). Since it is a comprehensive financial report for a period shorter than a full fiscal year (Q3), it falls under the Interim/Quarterly Report category. 9M 2017
2017-11-15 Polish
Zmiana terminu przekazania skonsolidowanego raportu kwartalnego Grupy Kapitałowej Selvita za III kwartał 2017 r. - Content (PL)
Report Publication Announcement Classification · 98% confidence The document text is very short (339 characters) and explicitly states that the consolidated quarterly report for Q3 2017, which was previously scheduled for November 16, 2017, will now be published on November 15, 2017. This is an announcement about the timing/publication of a report, not the report itself. According to Rule #2 (The 'Menu vs Meal' Rule), a short document announcing the publication of a report should be classified as a Report Publication Announcement (RPA). The Polish text translates to an announcement regarding the publication date change of the quarterly report.
2017-10-30 Polish
Zawarcie znaczącej umowy dotacji z NCBiR - Content (PL)
Regulatory Filings Classification · 95% confidence The document is a formal announcement from the Management Board ('Zarząd Selvita S.A.') detailing the signing of a significant agreement ('Umowa') with the National Centre for Research and Development ('Narodowym Centrum Badań i Rozwoju') for project funding. It specifies the total value, the amount of funding, and the project timeline (2017-2022). This type of announcement, concerning significant contracts, funding, or strategic project updates that impact the company's operations and financial standing, typically falls under general regulatory disclosures. Since it is not a standard financial report (10-K, IR, ER), a management discussion (MDA), or a capital event (CAP), and it relates to a significant business development, it best fits the general 'Regulatory Filings' category (RNS) as a miscellaneous, material disclosure, or potentially 'Capital/Financing Update' (CAP) due to the funding aspect, but RNS is broader for material non-standard announcements. Given the context of a significant contract award and funding, RNS is the most appropriate fallback for a material, non-standard regulatory disclosure.
2017-10-11 Polish
Powiadomienia akcjonariuszy
Director's Dealing Classification · 99% confidence The document is titled "Powiadomienie o transakcji/transakcjach*, o którym mowa w art. 19 ust. 1 rozporządzenia MAR" (Notification of a transaction(s) referred to in Article 19(1) of the MAR Regulation). It details transactions involving shares ('Akcja') by a person discharging managerial responsibilities ('Paweł Przewięźlikowski', Prezes Zarządu - CEO/President of the Management Board). Article 19 of the Market Abuse Regulation (MAR) specifically mandates reporting of transactions by persons discharging managerial responsibilities (PDMRs). This directly corresponds to the definition of Director's Dealing (insider trades). The filing type code 'DIRS' (Director's Dealing) is the most appropriate classification, as it covers reports of personal share transactions by company directors and executives.
2017-10-10 Polish
Informacja o transakcjach nabycia akcji uzyskana w trybie art. 19 MAR - Content (PL)
Director's Dealing Classification · 98% confidence The document text is very short (616 characters) and explicitly states that the Management Board received notifications ('powiadomienia') regarding transactions (acquisitions of shares) from key executives (CEO, Vice-CEO, Director) concerning Article 19 of the MAR Regulation. It concludes by stating that the company is attaching the content of these notifications ('W załączeniu Spółka przekazuje treść otrzymanych Powiadomień'). This structure—a brief announcement about receiving and attaching insider transaction reports—strongly suggests a notification of director's dealings. The specific mention of transactions by directors/executives aligns perfectly with the 'Director's Dealing' definition (Code: DIRS). Although it involves attaching documents, the core subject matter is the insider trade notification itself, making DIRS more specific than RPA or RNS.
2017-10-10 Polish
Czasowe wstrzymanie badań klinicznych w ramach projektu SEL24 przez FDA - Content (PL)
Legal Proceedings Report Classification · 98% confidence The document text is a formal notification from the management board ('Zarząd Selvita S.A.') regarding a significant regulatory action taken by the US Food and Drug Administration (FDA). Specifically, the FDA has ordered a suspension of a clinical trial (SEL24 phase I/II) due to a serious adverse event (death following a stroke). This content directly relates to legal, regulatory, and safety matters concerning the company's product pipeline. This fits the definition of a Legal Proceedings Report (LTR), which covers significant lawsuits, regulatory actions, or legal matters involving the company. It is not an earnings release, an annual report, or a general regulatory filing (RNS), as it details a specific, adverse regulatory event.
2017-10-09 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.